ArticleFrontiers in medicine2026
Pilot validation of the genital psoriasis reported outcomes questionnaire in an Italian cohort.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Genital psoriasis is a highly impactful but frequently under-recognized manifestation of psoriasis, associated with pain, burning, pruritus, and substantial impairment in sexual, relational, and emotional wellbeing. Existing patient-reported outcome measures (PROMs), such as the Genital Psoriasis Symptoms Scale (GPSS) and the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ), evaluate isolated domains (physical symptoms or sexual functioning) and do not provide a multidimensional assessment of the specific burden associated with genital psoriasis. To address this gap, the Genital Psoriasis Reported Outcomes (GPRO) questionnaire was developed. This study represents the first pilot psychometric validation of the GPRO questionnaire in an Italian cohort. Objective: The study aimed to assess the feasibility, internal consistency, construct validity, structural validity, and responsiveness of the GPRO questionnaire in adult patients with genital psoriasis initiating systemic therapy. Methods: A monocentric, prospective, observational pilot study was conducted, enrolling 57 adults with clinically confirmed genital psoriasis. Assessments were performed at baseline (T0) and at week 16 (T1). Participants completed the GPRO questionnaire, GPSS, and GenPs-SFQ, and clinicians assessed disease severity using the modified version of the Physician's Global Assessment of Genitalia (gPGA) and the Psoriasis Area and Severity Index (PASI). Analyses adhered to COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guidance and included assessments of internal consistency (Cronbach's Results: The GPRO questionnaire showed excellent internal consistency ( Conclusion: The GPRO questionnaire demonstrated strong preliminary psychometric performance, including internal consistency, construct validity, and responsiveness. As a multidimensional PROM, it captures different aspects of genital psoriasis. These findings support the feasibility of the GPRO questionnaire and justify further evaluation in larger multicentric studies for full validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.